Clinical Trials Logo
  1. Home
  2. Hidradenitis Suppurativa (HS)
  3. NCT06241573

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

Hidradenitis Suppurativa (HS) Clinical Trial

Official title:
Lunsayil LTE: An Extension Trial Assessing Long-term Spesolimab Treatment in Patients With Hidradenitis Suppurativa (HS)

Clinical Trial Summary

This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or study 1368-0100). The purpose of this study is to find out how well people tolerate spesolimab and whether it helps people with HS in the long-term. For about 1.5 years, participants get spesolimab injections under the skin every 2 weeks. Participants are in the study for about 2 years. During this time, participants have 41 visits. 24 visits are done at the study site. 17 visits can be done by video call at the participant's home. At study visits, doctors check the severity of the participant's HS and collect information on any health problems of the participants.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06241573
Study type Interventional
Source Boehringer Ingelheim
Contact Boehringer Ingelheim
Phone 18002430127
Email clintriage.rdg@boehringer-ingelheim.com
Status Recruiting
Phase Phase 2/Phase 3
Start date April 16, 2024
Completion date April 17, 2030
View Details
See also
  Status Clinical Trial Phase
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Completed NCT02896920 - Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness
Completed NCT01468233 - Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa Phase 3
Completed NCT01468207 - Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Phase 3
Completed NCT03894956 - Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
Completed NCT03001115 - Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects
Not yet recruiting NCT05723757 - Autophagy Dysfunction in Hidradenitis Suppurativa N/A
Completed NCT02808975 - Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically Phase 4
Completed NCT04430855 - A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms Phase 2
Recruiting NCT06212999 - A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa Phase 3
Active, not recruiting NCT04354012 - Hidradenitis Suppurativa Wound Care Phase 2
Completed NCT03487276 - Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Recruiting NCT05620836 - A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 3
Not yet recruiting NCT05735925 - The Role of Host-microbiota Interplay in Hidradenitis Suppurativa Pathogenesis N/A
Recruiting NCT05620823 - A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa Phase 3
Available NCT05583604 - Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)